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Background: There is little knowledge concerning the content and the mechanisms of filling of arachnoid cysts.
The aim of this study was to compare the protein content of arachnoid cysts and cerebrospinal fluid by
quantitative proteomics to increase the understanding of arachnoid cysts.
Methods: Arachnoid cyst fluid and cerebrospinal fluid from five patients were analyzed by quantitative proteomics
in two separate experiments.
In a label-free experiment arachnoid cyst fluid and cerebrospinal fluid samples from individual patients were trypsin
digested and analyzed by Orbitrap mass spectrometry in a label-free manner followed by data analysis using the
Progenesis software.
In the second proteomics experiment, a patient sample pooling strategy was followed by MARS-14 immunodepletion
of high abundant proteins, trypsin digestion, iTRAQ labelling, and peptide separation by mix-phase chromatography
followed by Orbitrap mass spectrometry analysis. The results from these analyzes were compared to previously
published mRNA microarray data obtained from arachnoid membranes.
Results: We quantified 348 proteins by the label-free individual patient approach and 1425 proteins in the iTRAQ
experiment using a pool from five patients of arachnoid cyst fluid and cerebrospinal fluid. This is by far the largest
number of arachnoid cyst fluid proteins ever identified, and the first large-scale quantitative comparison between the
protein content of arachnoid cyst fluid and cerebrospinal fluid from the same patients at the same time. Consistently in
both experiment, we found 22 proteins with significantly increased abundance in arachnoid cysts compared to
cerebrospinal fluid and 24 proteins with significantly decreased abundance. We did not observe any molecular weight
gradient over the arachnoid cyst membrane. Of the 46 proteins we identified as differentially abundant in our study, 45
were also detected from the mRNA expression level study. None of them were previously reported as differentially
expressed. We did not quantify any of the proteins corresponding to gene products from the ten genes previously
reported as differentially abundant between arachnoid cysts and control arachnoid membranes.
Conclusions: From our experiments, the protein content of arachnoid cyst fluid and cerebrospinal fluid appears to be
similar. There were, however, proteins that were significantly differentially abundant between arachnoid cyst fluid and
cerebrospinal fluid. This could reflect the possibility that these proteins are affected by the filling mechanism of
arachnoid cysts or are shed from the membranes into arachnoid cyst fluid. Our results do not support the proposed
filling mechanisms of oncotic pressure or valves.* Correspondence: magnus.berle@gmail.com
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Arachnoid cysts (AC) are congenital malformations of
the arachnoid; a benign malformation with reported
prevalence of up to 1.1% [1,2]. The mechanism of forma-
tion of such cysts is not known, although several studies
have tried to investigate and understand the biological
basis of AC [3-11]. Anatomically, ACs originate from
splitting of the arachnoid mater (AM), thus ACs are
truly intra-arachnoid in nature [9,10]. True ACs are con-
sidered to be developmental or congenital mistakes of
the arachnoid architecture [12]. By electron microscopy,
Rengachary et al. [10] observed that the inner mem-
brane of AC is covered by hyperplastic arachnoid cells,
as well as cells in the cyst membrane – resembling foetal
human arachnoid cells.
Using chemical analyses on AC fluid, Sandberg et al.
[7] observed a composition comparable with cerebro-
spinal fluid (CSF). In addition, they found that some
cysts had elevated protein levels in their fluid, relative to
reference values. In a previous study on AC fluid and
CSF from the same patient population as the current
study, Berle et al. [4] found AC fluid and CSF to be
similar in electrolyte content, except for an increased
phosphate content in cyst fluid. The following compo-
nents were reduced in AC fluid compared with CSF: 1)
the total protein amount 2) lactate dehydrogenase and
ferritin. Based on the decrease in protein concentration,
we would suspect a molecular weight gradient, although
the number of measured proteins was low.
Helland et al. [5] and Aarhus et al. [6] found differen-
tially expressed mRNA and DNA copy number in AC
membrane relative to normal arachnoid membrane for the
genes NKCC1 [5] and ASGR1, DPEP2, SOX9, SHROOM3,
A2BP1, ATP10D, TRIML1, BEND5 and NMU [6]. The
NKCC1 is an active salt pump, that conceptually could
contribute to the filling of AC. Zeuthen [13] discussed
water transport in tissues against osmotic barriers and sug-
gested that this transport is energised by ion transport,
thus opening for active or selective transport as a filling
mechanism. For active pumps such as the sodium – potas-
sium – chloride transporter NKCC1, the amount of water
co-transported is interesting - a single load of 1 Na+, 1 K+,
2 Cl- may co-transport as much as 590 H20-molecules.
In the same patient population as the current study,
Berle et al. [11] performed a qualitative proteomics study
of AC fluid, where the 199 identified proteins in a pool
from 11 individual patients did show a similar protein ex-
pression as in normal CSF (195/199 proteins), dissimilar
from that of plasma. A qualitative protein comparison
study between 14 patients did indicate AC fluid protein
profiles to be relatively homogenous between patients.
Label-free quantitative proteomics by measured precursor
intensity is a well-established method for obtaining relative
quantitative measurements of a large number of proteinsbetween samples [14]. Quantitative proteomics by Isobaric
tag for relative and absolute quantification (iTRAQ) [15] al-
lows for extensive fractionation at the peptide level of sam-
ples pooled after labelling without loosing analytical
reproducibility. The possibility for extensive fractionation
makes it possible to identify and quantify a larger portion
of the proteome. This method requires a significantly larger
amount of sample material. The quantitative proteomics
methods applied here have been described thoroughly else-
where [16].
In this study we used proteomics to quantitatively
compare the protein content of AC fluid and CSF from
the same patients, in order to identify possible differ-
ences in the proteomes between these two fluids. Two
different approaches were undertaken; one where sam-
ples from individual patients were analysed using a
label-free approach, and one where individual patient
samples were pooled, iTRAQ-labelled and extensively
fractionated to allow for a more in-depth quantitative
analysis of the proteomes. The two complementary pro-
teomics approaches were expected to give us a better
insight in the content of AC fluid and potentially the
mechanisms of fluid filling. Furthermore, we wanted to
use the quantitative data to evaluate previously pub-
lished results on AC, both to test the hypothesis of a
molecular weight gradient over the AC membrane, and




Patients were recruited by the responsible surgeon and
had signed a written informed consent. This project was
approved by the Regional Committee for Medical and
Health Research Ethics (REK) of Western Norway (ap-
provals REK 70.03, NSD 9634 and REK 2009/1885).
Five participants, two males, three females, age 22–60
years, with unilateral temporal ACs were included in
this study. AC fluid was collected during decompressive
cyst surgery at Haukeland University Hospital (Bergen,
Norway). The samples were selected from our biobank
that contains samples of AC fluid and CSF from the
same patients. All the patients fulfilled the following cri-
teria: no previous intracranial surgery, no intracranial
bleeding or trauma, and relatively low intraoperative
blood contamination in both AC fluid and CSF as esti-
mated from visual inspection and measured by mass
spectrometry. An overview of the patients included is
presented in Table 1.
Sample collection
The methods for sample collection and handling proto-
col as well as the laboratory work-up used in this study
have previously been described in detail [4,17]. Briefly,
Table 1 Age, gender and protein concentration in AC fluid and CSF for the included patients
Patient number Age Gender Protein concentration AC fluid μg/μl Protein concentration CSF μg/μl
1 26 f 0.44 0.57
2 43 m 0.38 0.62
3 22 f 0.31 0.59
4 41 f 0.29 0.59
5 60 m 0.50 0.59
Average 0.38 0.59
protein content ratio AC fluid/CSF 0.65
Figure 1 Overview of procedures undertaken.
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(craniotomy with fenestration and extirpation of the
cyst) by puncturing the dura with a 23G, 25 mm long
syringe needle using an Optidynamic® spinal fluid man-
ometer (Mediplast AB, Malmo, Sweden) as siphon,
through a burr hole before the craniotomy and opening
of the dura. The fluid was centrifuged at 450× g for 5
min to remove cells and cell debris, and the supernatant
was aliquoted and frozen at −80°C. Deviations and ob-
servations on individual sample material were noted on
sampling.
After opening the medial cyst membrane that covered
the basal structures (tentorial slit, oculomotor nerve, ca-
rotid artery, and the optic nerve), thus creating commu-
nication to the basal cisterns and the posterior fossa, a
CSF-sample was collected with a pre- cut baby-feeding
catheter #6, connected to a 10 ml syringe. The catheter
was placed below the tentorium via the tentorial slit and
fluid was aspirated gently from the posterior fossa. The
collected CSF was processed in the same manner as the
cyst fluid.
Chemicals
Trypsin was purchased from Promega (Fitchburg WI,
USA). N-octyl-β-D-glycopyranoside (NOG) was purchased
from Anatrace (Maumee, OH, USA). Urea, acetonitrile
(ACN), formic acid (FA), calcium chloride (CaCl2), iodo-
acetamide (IAA) and dithiothreitol (DTT), potassium phos-
phate monobasic (KH2PO4), potassium chloride (KCl),
water and trifluoroacetic acid (TFA) were purchased from
Sigma-Aldrich (St. Louis MO, USA). Water and ACN were
of HPLC quality.
Label free sample preparation
A flow chart of the label-free proteomics experiment com-
paring the protein content between AC fluid and CSF for
five individual patients is given in Figure 1. The protein
concentration in AC fluid and CSF was measured using a
QubitTM fluorometer (Life Technologies, Carlsbad CA,
USA). The individual AC fluid and CSF samples were con-
centrated and desalted using Amicon 3 kDa molecular
weight cut-off filters (Millipore, Billerica, MA, USA) anddried in a vacuum concentrator (Eppendorf, Hamburg,
Germany). The proteins were digested into peptides by
trypsin as described [18], a brief summary follows: the
dried protein pellet was dissolved in 6 M Urea and 100 mM
DTT and incubated for 1h at room temperature (RT).
Cysteins were alkylated using 200 mM iodoacetamide dur-
ing one hour incubation at RT. Chymotrypsin activity was
inhibited by adding 2 mM CaCl2 and the proteins were
digested to peptides over night at 37°C using trypsin (Se-
quencing Grade Modified Trypsin, Promega) at a protein:
trypsin ratio of 1:50. Each sample was acidified using 10%
FA to quench the digestion activity, desalted and concen-
trated on an Oasis HLB μElution Plate (Waters) as previ-
ously described [14] followed by drying the sample
completely in a vacuum concentrator.
Sample preparation prior to iTRAQ-labelling
A flow chart of the iTRAQ proteomics experiment com-
paring the protein content between AC fluid and CSF
pooled from five patients is given in Figure 1. AC fluid
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erate a pool of 750 μl, and a pool of CSF was made in
the same way for the same patients. 250 μl of each of
these two pools were combined into a mix-pool. 500 μl
from each of the AC fluid pool, CSF pool and mix-pool
was concentrated using 3 kDa ultracentrifugation filters
(Amicon Ultra-4, Millipore, Bedford, MA), which were
pre-rinsed with 0.1% NOG. The samples were then de-
pleted of high abundant proteins using a human Multiple
Affinity Removal System (MARS Hu-14) 4.6 mm× 50 mm
LC column (Agilent Technologies) according to the proto-
col provided by the supplier, using a Dionex 3000-series
LC system. This column depletes albumin, IgG, antitrypsin,
IgA, transferrin, haptoglobin, fibrinogen, alpha-2-macro-
globulin, alpha-1-acid glycoprotein, IgM, apolipoprotein
AI, apolipoprotein AII, complement C3, and transthyretin.
The high-abundant protein-depleted samples were concen-
trated using 3 kDa ultracentrifugation filters which were
pre-rinsed with 0.1% NOG. Each sample was freeze-dried
prior to protein digestion and iTRAQ labelling.Protein digestion and iTRAQ-labelling
For the pooled patient samples, the total protein in
each depleted sample was reduced, alkylated, digested
with trypsin, and iTRAQ-labelled according to the
manufacturer‘s protocol using the reagents provided
(Applied Biosystems, Foster City, CA). The reduced
and S-methylmethanethiosulfonate (MMTS)-treated
proteins were digested to peptides over night at 37°C
using 2.5 μg trypsin as protease. The peptides were
iTRAQ-labelled (4plex) where the mix-pool 50:50 AC
fluid and CSF with the 114 label, the AC fluid with the
115 label, and CSF with the 116 label. All samples were
combined after the labelling was conducted.Mix-phase chromatograpy
iTRAQ labelled peptides were fractionated in 28 frac-
tions using mix-phase chromatography utilizing a Sielc
Promix column (MP-10.250.0530, 1.0 × 250 mm, 5 μm,
300Å, Sielc Technologies, Prospect Heights, Illinois),
using an Agilent 1260 series LC system (Agilent Tech-
nologies, Palo Alto, CA). The peptides were recons-
tituted in buffer A (20 mM ammonium formate, 3%
ACN) and loaded on the Mix phase column using 85%
A for 10 min at a flowrate of 50 μl/min. The peptides
were eluted using a gradient of 15% - 60% buffer B (2
mM ammonium formate, 80% ACN, pH 3.0) over 35
min, 60%-100% B over 10 min and held constant for
5 min. The fractions were collected every 2 min until
60 min, the last 10 min of the LC run was collected
in 2 fractions of 5 min. The fractions from the 8 first
min of the gradient were discarded.Orbitrap mass spectrometry
Injection and LC
For the label-free experiment, 0.5μg (as determined by
the protein concentration measurement) of each pep-
tide sample dissolved in 1% aqueous formic acid, was
injected into an Ultimate 3000 RSLC system (Thermo
Scientific, Sunnyvale, California, USA) connected online
to a linear quadrupole ion trap-Orbitrap (LTQ-Orbitrap
Velos Pro) mass spectrometer (Thermo Scientific, Bremen,
Germany) equipped with a nanospray Flex ion source
(Thermo Scientific). The sample was loaded and desalted
on a pre-column (Acclaim PepMap 100, 2 cm × 75 μm i.d.
nanoViper column, packed with 3μm C18 beads) at a flow
rate of 5μl/min for 6 min using an isocratic flow of 0.1%
FA (vol/vol) with 2% ACN (vol/vol).
Peptides were separated during a biphasic ACN gradient
from two nanoflow UPLC pumps with flow rate of 280 nl/
min on the analytical column (Acclaim PepMap 100, 15
cm x 75μm i.d. nanoViper column, packed with 2μm C18
beads). Solvent A was 0.1% FA (vol/vol) with 2% ACN
(vol/vol). Solvent B was 0.1% FA (vol/vol) with 90% ACN
(vol/vol). The gradient composition was 5–38% B from LC
starts to 67 min, then 38–90% B from 67–70 min. 90% B
was held constant for 5 min, followed by column condi-
tioning for 12 min with 5% B.
Individual patient samples
The eluting peptides were ionised in the electrospray
and analyzed by the LTQ-Orbitrap Velos Pro. The mass
spectrometer was operated in the DDA-mode (data-
dependent-acquisition) to automatically switch between
full scan MS and MS/MS acquisition.
Survey full scan MS spectra (from m/z 300 to 2000) were
acquired in the Orbitrap with resolution R = 60000 at m/z
400 (after accumulation to a target value of 1e6 in the linear
ion trap with maximum allowed ion accumulation time of
500ms). The seven most intense eluting peptides above an
ion threshold value of 1000 counts, and charge states 2 or
higher, were sequentially isolated to a target value of 1e4
and fragmented in the high-pressure linear ion trap by
low-energy CID (collision-induced-dissociation) with nor-
malised collision energy of 40% and wideband-activation
enabled. The maximum allowed accumulation time for
CID was 200ms, the isolation width maintained at 2Da, ac-
tivation q = 0.25, and activation time of 10ms. The resulting
fragment ions were scanned out in the low-pressure ion
trap at normal scan rate, and recorded with the secondary
electron multipliers. One MS/MS spectrum of a precursor
mass was allowed before dynamic exclusion for 30s. Lock-
mass internal calibration was not enabled.
Pooled patient samples
The settings were identical to those mentioned above for
CID fragmentation, with the exception that the seven
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in the high-pressure linear ion trap by low-energy CID
and in the octopole HCD collision cell by HCD (Higher
Energy Collision Dissociation) fragmentation. Both frag-
mentation forms used normalised collision energy of
40%. For HCD fragmentation the isolation width was
3Da and the activation time 0.10ms. After fragmentation
in the HCD cell the fragments were transferred via the
C-trap to the Orbitrap and scanned out with resolution
R = 7500. One MS/MS spectrum of a precursor mass
was allowed before dynamic exclusion for 20s.
Data analysis
The handling of multiple testing and validation of pep-
tide and protein hits were assessed by false discovery
rate (FDR) [19]. The data from the individual patients’
label-free experiment were compared by paired 2-sided
t-test with p < 0.05.
The individual patient data obtained from the label-
free quantitative analysis was compared using Progenesis
LC-MS (Nonlinear Dynamics Ltd. Newcastle upon Tyne,
UK) (v4.0.4573.30654). The data was searched against
the SwissProtKB database (release 2011_10) using
SearchGUI (1.8.3) with OMSSA and XTandem as search
engines and PeptideShaker (0.16.2) (http://code.google.
com/p/peptide-shaker/) for combining the results [20].
The following search criteria were used: fixed modifica-
tions carbamidomethylation, oxidated methionine as
variable modification, a maximum of two missed cleav-
ages, precursor mass tolerance 15 ppm, and product
mass tolerance 0.7 Da. The peptides were auto-validated
with maximum FDR of 1.0%. The quantitative data
obtained from the individual patients in the label-free
experiment was compared by a paired 2-sided t-test.
Proteins with a p-value of less than 0.05 combined with
an average fold change of more than +/− log2 (0.58)
were considered as differentially abundant between CSF
and AC fluid.
The pooled patient iTRAQ-data was searched using
the Spectrum Mill software package v4.0 (Agilent Tech-
nologies, Santa Clara, CA) using the same settings as
previously described [14]. MS/MS data was searched
against the SwissProtKB database (release 2011_10)
with a precursor mass tolerance of 15 ppm, and a prod-
uct mass tolerance 0.7 Da. The peptides were validated
by auto-determined score by delta R1-R2 threshold with
max FDR of <1.2%. Proteins were validated by mini-
mum protein score of 20. To normalize the data, we re-
centred the protein ratios of each sample versus the
reference sample by subtracting the median in each
iTRAQ channel from each ratio so that the distribution
was symmetrical around a log2 ratio of 0, as described
elsewhere [17]. The reference/CSF value was divided by
the reference/AC fluid value for every protein to obtaina CSF-to-AC fluid ratio. All proteins with a fold change
more than +/− log2 (0.58) were considered as differen-
tially abundant between CSF and AC fluid.
Using the bioinformatics software J-Express Pro 2.7
(MolMine AS, Bergen, Norway) proteins with increased
or reduced abundance between CSF and AC fluid in
both label-free and iTRAQ labelled experiments were
compared with the corresponding gene expression pro-
files of a previously published study [6]. The objective of
this examination was to evaluate whether AC fluid pro-
tein expression could be linked to membrane mRNA ex-
pression. The proteins were searched in PubMed for
official gene symbol, and then searched against the
microarray data to obtain the corresponding mRNA ex-
pression profile.
Gene ontology data for the identified proteins in the
iTRAQ experiment were obtained using ProteinCenter
version 3.9.10025 (Thermo-Fischer scientific, Odense,
Denmark).
Results
In the quantitative individual label-free comparison, we
quantified 348 proteins, of which 150 were differentially
expressed between AC and CSF (p < 0.05 in a paired two-
sided t-test, minimum 2 peptides, FDR < 1.0%). In the
iTRAQ-labelled quantitative experiment, 1425 proteins
were identified (minimum 2 peptides, FDR <1.2%). 296
protein groups were identified both in the label-free and
the iTRAQ-labelled experiment. The list of proteins iden-
tified from the quantitative iTRAQ-labelled experiment,
ranked by fold change AC/CSF, is presented in Additional
file 1: Table of Proteins identified in the iTRAQ-labelled
experiment. Proteins identified in the label-free experi-
ment with individual and average fold change, p-value,
and corresponding iTRAQ fold change value (when ap-
plicable) are shown in Additional file 2: Table of proteins
identified in the label-free experiment. The iTRAQ quan-
tification experiment is also the single largest qualitative
characterization of AC fluid proteins. The 1425 proteins
identified and quantified in the iTRAQ-experiment were
annotated to a multitude of cellular localizations, of which
the principal classes are presented in Figure 2. A high pro-
portion of the proteins were annotated to extracellular or
membrane space. Note that one protein may be allocated
to several localizations and may therefore be counted
more than once.
We found 22 proteins with significantly higher abun-
dance in the AC fluid relative to CSF and 24 proteins
with significantly lower abundance (Table 2). These pro-
teins were selected on significant differential abundance
by t-test between individual samples, as well as fold
change +/− log2 (0.58) in both individual label-free sam-
ples and iTRAQ-labelled samples. Concerning the pro-
teins with changed abundance in AC fluid relative to
Figure 2 Genetic Ontology of cellular localization of the 1425 quantified protein groups in the iTRAQ-labeled pooled patient samples.
Figure made utilizing ProteinCenter version 3.9.10025.
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teins. Some, but not all, of the proteins with reduced
abundance in AC relative to CSF are typical blood
proteins. Examples of such proteins were carbonic
anhydrase 1, fibrinogen, alpha-1-antitrypsin and hae-
moglobin. Carbonic anhydrase 1 has previously been
reported to be present in CSF due to contamination of
blood introduced during sample collection [21].
Among the proteins being more abundant in AC fluid
was ribonuclease T2 (Gene name: RNASET2). Defects in
RNASET2 are proposed to be the cause of cystic leuko-
encephalopathy without megalencephaly (LCWM), and
the brain of such affected individuals shows anterior
temporal lobe subcortical cysts.
We were not able to link the molecular functions of
the 46 differentially abundant proteins to the cyst fluid
biology based on the examined GO functional terms and
Uniprot functional annotation (data not shown). The
cellular location of the differentially abundant proteins
between AC fluid and CSF were mainly membrane and
secreted proteins as seen from the GO analysis (data not
shown).
In the iTRAQ quantification, we identified 1129 pro-
teins that were not present in the list from the label-free
experiment. The use of depletion for the most abundant
proteins as well as more extensive fractionation caused
this increase in the number of proteins quantified. We
observed that 480 of the proteins quantified in the
iTRAQ experiment were outside the selected boundaries
of significant fold change (+/− log2 (0.58)), but we can-
not from this experiment conclude if any of these pro-
teins represent a true biological change in abundance
without additional verification. We observed that these
480 proteins to a lesser degree seem to representmembrane or extracellular proteins, relative to the pro-
teins reported as differential abundant in both experi-
ments (data not shown).
From the 46 proteins we identified as differentially
abundant in our study, 45 were also detected from the
mRNA expression level study. None of them were
reported as differentially expressed [6]. We identified
no specific patterns of altered abundance between the
membrane mRNA and the 46 differentially abundant
cyst fluid proteins (Additional file 3: Comparison of
protein results versus mRNA data.). We did not quan-
tify any of the proteins associated with the ten genes
previously reported as differentially abundant between
AC membrane and AM [5,6] (data not shown).
To test the hypothesis of molecular weight gradients
over the AC membrane, we created a scatter plot for all
the iTRAQ protein ratios sorted based on protein molecu-
lar weight. We could not see any correlation between in-
creased molecular weight and decreased abundance in AC
compared to CSF from this plot (results not shown).Discussion
In this study, we identified by far the largest number of
AC fluid proteins ever reported, and this is also the first
large-scale quantitative comparison between the protein
content of AC fluid and CSF collected from the same
patients. At present, there are three dominating hypoth-
eses on the mechanisms of filling and sustaining of AC:
secretion or selective transport, oncotic filling, and a
slit-valve mechanism. Previous reports of reduced pro-
tein content in AC fluid relative to CSF [4,7] in the same
sample population as the current study do weaken the
hypothesis of filling by oncotic pressure.
Table 2 Overview of the quantitative protein results from the comparison of the two experiments
Accession
number








O94772 Lymphocyte antigen 6H 4 3 0,023 9,7 1,5
P13987 CD59 glycoprotein 4 3 0,033 5,6 1,6
P16070 CD44 antigen 4 3 0,026 2,3 2,0
P55058 Phospholipid transfer protein 17 7 0,026 2,2 2,2
P01033 Metalloproteinase inhibitor 1 7 4 0,019 2,0 2,0
O00584 Ribonuclease T2 14 3 0,010 2,0 2,3
P02747 Complement C1q subcomponent subunit
C
2 4 0,013 1,9 1,4
P48745 Protein NOV homolog 9 3 0,011 1,9 1,7
P07602 Proactivator polypeptide 15 9 0,042 1,9 1,7
P10909 Clusterin 25 26 0,001 1,8 1,9
Q969P0 Immunoglobulin superfamily member 8 8 4 0,008 1,7 1,7
Q9Y6R7 IgGFc-binding protein 27 9 0,002 1,7 2,2
Q6UX71 Plexin domain-containing protein 2 14 3 0,008 1,6 1,8
Q02246 Contactin-2 35 19 0,011 1,6 2,2
P04066 Tissue alpha-L-fucosidase 11 2 0,009 1,6 2,7
Q96GW7 Brevican core protein 27 11 0,016 1,6 1,6
P08253 72 kDa type IV collagenase 31 5 0,005 1,6 1,9
Q15113 Procollagen C-endopeptidase enhancer 1 16 10 0,010 1,5 1,8
P08571 Monocyte differentiation antigen CD14 14 9 0,000 1,5 1,6
O75509 Tumor necrosis factor receptor
superfamily member 21
7 3 0,018 1,5 1,6
P20062 Transcobalamin-2 11 2 0,036 1,5 2,9
Q12860 Contactin-1 44 18 0,003 1,5 1,6
P60174 Triosephosphate isomerase 15 8 0,020 0,6 0,4
Q99497 Protein DJ-1 15 4 0,036 0,5 0,4
P19827 Inter-alpha-trypsin inhibitor heavy chain
H1
19 7 0,032 0,5 0,3
P19823 Inter-alpha-trypsin inhibitor heavy chain
H2
24 7 0,032 0,5 0,4
P06744 Glucose-6-phosphate isomerase 16 3 0,034 0,4 0,3
P09382 Galectin-1 5 4 0,041 0,4 0,4
P62258 14-3-3 protein epsilon 16 4 0,032 0,3 0,2
P63104 14-3-3 protein zeta/delta 14 3 0,027 0,3 0,3
P04040 Catalase 18 2 0,001 0,3 0,2
P62937 Peptidyl-prolyl cis-trans isomerase A 11 4 0,022 0,3 0,2
P09211 Glutathione S-transferase P 9 6 0,029 0,3 0,3
P32119 Peroxiredoxin-2 12 4 0,001 0,3 0,1
P00558 Phosphoglycerate kinase 1 25 4 0,036 0,3 0,3
P02675 Fibrinogen beta chain 16 12 0,003 0,3 0,5
P08107 Heat shock 70 kDa protein 1A/1B 27 5 0,034 0,3 0,2
P02671 Fibrinogen alpha chain 14 8 0,001 0,3 0,5
P63261 Actin, cytoplasmic 2 21 5 0,020 0,2 0,1
P07437 Tubulin beta chain 8 2 0,033 0,2 0,2
P02679 Fibrinogen gamma chain 5 10 0,001 0,2 0,5
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Table 2 Overview of the quantitative protein results from the comparison of the two experiments (Continued)
P02042 Hemoglobin subunit delta 14 7 0,008 0,2 0,1
P00915 Carbonic anhydrase 1 9 5 0,004 0,2 0,0
P68871 Hemoglobin subunit beta 14 12 0,006 0,2 0,0
P08670 Vimentin 33 27 0,027 0,2 0,1
P69905 Hemoglobin subunit alpha 10 13 0,003 0,1 0,0
Proteins with different abundance between AC fluid and CSF, determined by significant (p < 0.05) differential abundance in individual label-free samples, as well
as fold change +/− log2 (0.58) in both label-free and iTRAQ experiment.
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we identified 46 proteins with altered abundance be-
tween AC fluid and CSF. Some of the protein groups
with lower abundance in AC fluid seem to have a high
representation of blood proteins. Blood contamination is
an obvious problem when sampling is not identical be-
tween the sample types to be compared, in this case AC
fluid and CSF. Because we sample AC fluid through a
syringe needle after a direct puncture of the cyst, the
risk for blood contamination of the cyst fluid is low. CSF
is collected in the basal cistern after the operation is fin-
ished and haemostasis is ensured. This might lead to a
small and variable contamination of blood in the CSF
samples. Hence, abundance changes in these typical
blood proteins are probably not representing AC biol-
ogy, but are rather introduced to CSF during sample col-
lection. Currently, there is no consensus on how to
handle skewed blood contamination. Most of the pro-
teins with reduced abundance in AC relative to CSF are
however not termed “blood specific” proteins.
A challenge in the evaluation of quantitative difference
is the defining criteria on what is differentially abundant
protein. In our case, we choose to include proteins that
were observed with fold change above +/− log2 (0.58) in
both experiments, as well as a p-value below 0.05 for the
label-free experiment. This result might be somewhat
conservative for exploratory analyses; hence we also
evaluated the abundance changes for the 1129 proteins
only quantified in the iTRAQ study.
The 480 proteins from the iTRAQ study with fold
change above +/− log2 (0.58) in this analysis does how-
ever need further verification in different sample sets, by
different methods or specific validation by for example
selective reaction monitoring to increase the certainty of
these findings. Further verification is also necessary to
confirm the differential abundance of the 46 proteins
found as differentially abundant in both experiments in
a larger number of patients. Our current results give
however support to the previous claim [4] that AC fluid
is different from CSF. As observed from our Qubit pro-
tein measurements, the general trend of reduced total
protein concentration in AC fluid relative to CSF does
not support oncotic pressure gradients. Observingdifferential abundance of proteins between AC fluid and
CSF, as well as the lack of observed slit valves in general
in the literature, do in principle not support the theory
of valve mechanism. In case of a valve mechanism, we
would expect a higher similarity in the quantitative
proteomes between AC fluid and CSF than what we ob-
serve to support this theory. In addition, to the authors’
knowledge, slit valves have only been observed in
suprasellar AC and not in temporal AC. We therefore
believe that such valve mechanisms are less likely to be
responsible for AC filling, but we do not have definitive
evidence against it. Differential abundance of proteins
between AC fluid and CSF is supportive of some kind of
secretion or selective transport, but we are not able to
elute which on basis of our results.
Previous reports have identified an up-regulation of
mRNA for several ion transporters [5] and other genes [6]
in AC membrane when compared with normal arachnoid
membrane. In our proteomics study, we hypothesised that
some of the proteins in the AC membrane corresponding
to these mRNA transcripts also could be found in the AC
fluid, but not to the same extent in CSF, and that such
proteins possibly could give an indication of the mechan-
ism of transport over the membrane. However, we were
not able to draw such lines based on our obtained data.
Concerning the proteins that make up active pumps, such
as NKCC1, they would be a part of the AC wall and thus
not necessarily detectable in AC. A lack of confirmation in
our data does therefore not exclude that such pumps can
be found in the AC membrane, in particular since hydro-
phobic membrane proteins might not at all be detectable
in the AC fluid due to solubility issues.
In a previous study, Berle et al. [4] suggested a MW
gradient from the reported reduced concentration of
macromolecules ferritin and lactate dehydrogenase. The
extended examinations of the data presented in the
current work, with the lack of correlation between quan-
titative ratios and molecular weight, contradict such a
hypothesis of MW gradients over the AC membrane.
Conclusions
From our experiments, the protein content of AC fluid
and CSF appears to be very similar. Some proteins were,
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AC fluid and CSF. This could reflect that these proteins
are affected by the filling mechanism of arachnoid cysts
or are shed from the membranes into arachnoid cyst
fluid, but we are not able to identify the mechanism. We
did not identify protein products in AC fluid from the
previously suggested pumps found in the AC membrane
or specific MW gradients in distribution of proteins be-
tween AC fluid and CSF. Our results do not support the
mechanisms of oncotic pressure or valves. Based on
these results we suggest that some sort of secretion or
selective transport causes AC filling across the AC
membrane.
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Additional file 1: Table of proteins identified in the iTRAQ-labelled
experiment. The proteins are ranked by fold change between AC fluid
and CSF.
Additional file 2: Table of proteins identified in the label-free
experiment. The proteins are reported with individual and average fold
change, p-value and corresponding iTRAQ fold change value (when
applicable).
Additional file 3: Comparison of protein results versus mRNA data.
The reported proteins with increased or decreased abundance in AC fluid
relative to CSF are plotted against corresponding membrane mRNA
microarray data in order of significance in membrane data.
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